The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study
Source
|
ENCEPHALE (n°6 vol 45 )
|
Auteur(s) :
|
ARTEGA DUARTE C, Aut. ; FAKRA Eric, Aut. ; VAN GILS C, Aut. ; GUILLON P, Aut.
|
Année de publication :
|
2019
|
Pages :
|
459-467
|
Mots-clés :
|
ETUDE DE COHORTE ;
SCHIZOPHRENIE ;
|
Résumé :
|
Schizophrenia entails a considerable humanistic and economic burden. Improved treatment continuity to antipsychotic therapy is paramount to reduce the risk of relapse. The novel three-monthly paliperidone palmitate treatment (PP3M) offers the longest dosing interval currently available in France. This study assesses its cost-effectiveness, versus the currently available one-monthly long-acting treatment (PP1M) in French schizophrenic patients.With slightly better QALY outcomes and a cost-saving effect when compared to PP1M, introducing PP3M is an improvement to the current treatment in France.[extrait du résumé d'auteur]
|